The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 09, 2024

Filed:

Sep. 28, 2018
Applicants:

Juno Therapeutics, Inc., Seattle, WA (US);

Editas Medicine, Inc., Cambridge, MA (US);

Inventors:

Cameron Brandt, Seattle, WA (US);

Brian Belmont, Brookline, MA (US);

Christopher Borges, Cambridge, MA (US);

Stephen Michael Burleigh, Seattle, WA (US);

Alexandra Croft, Seattle, WA (US);

Stephen Jacob Goldfless, Seattle, WA (US);

David Jeffrey Huss, Seattle, WA (US);

Yue Jiang, Seattle, WA (US);

Timothy G. Johnstone, Seattle, WA (US);

David Koppstein, Seattle, WA (US);

Hieu Nguyen, Seattle, WA (US);

Christopher Heath Nye, Seattle, WA (US);

Haley Peper, Seattle, WA (US);

Blythe D. Sather, Seattle, WA (US);

Sonia Timberlake, Seattle, WA (US);

Dean Y. Toy, Seattle, WA (US);

Queenie Vong, Seattle, WA (US);

Gordon Grant Welstead, Cambridge, MA (US);

James Sissons, Seattle, WA (US);

Assignees:

Juno Therapeutics, Inc., Seattle, WA (US);

Editas Medicine, Inc., Cambridge, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/705 (2006.01); A61K 35/17 (2015.01); A61P 31/20 (2006.01); A61P 35/00 (2006.01); C07K 14/725 (2006.01); C12N 9/22 (2006.01); C12N 15/11 (2006.01); C12N 15/90 (2006.01);
U.S. Cl.
CPC ...
C07K 14/7051 (2013.01); A61K 35/17 (2013.01); A61P 31/20 (2018.01); A61P 35/00 (2018.01); C12N 9/22 (2013.01); C12N 15/11 (2013.01); C12N 15/907 (2013.01); C12N 2310/20 (2017.05); C12N 2800/80 (2013.01);
Abstract

Provided are binding molecules, such as TCRs or antigen binding fragments thereof and antibodies and antigen-binding fragments thereof, such as those that recognize or bind human papilloma virus (HPV) 16, including HPV 16 E6 and HPV 16 E7. Also provided are engineered cells containing such binding molecules, compositions containing the binding molecules or engineered cells, and methods of treatment, such as administration of the binding molecules, engineered cells, or compositions.


Find Patent Forward Citations

Loading…